Literature DB >> 21680024

Risk of relapse in primary acute anterior uveitis.

Lili Grunwald1, Craig W Newcomb, Ebenezer Daniel, R Oktay Kaçmaz, Douglas A Jabs, Grace A Levy-Clarke, Robert B Nussenblatt, James T Rosenbaum, Eric B Suhler, Jennifer E Thorne, C Stephen Foster, John H Kempen.   

Abstract

PURPOSE: To evaluate the risk of and risk factors for a second episode (relapse) among patients with remitted primary anterior uveitis.
DESIGN: Retrospective cohort study. PARTICIPANTS: Patients with primary anterior uveitis presenting to 1 of 4 academic ocular inflammation subspecialty practices achieving remission of the primary episode within 90 days of initial uveitis diagnosis.
METHODS: Data were obtained by standardized chart review. MAIN OUTCOME MEASURES: Time to relapse of anterior uveitis and risk factors for relapse.
RESULTS: We included 102 patients with a first episode of anterior uveitis who were seen within 90 days of first-ever uveitis onset and followed for 165 person-years after achieving remission of the initial episode. Most patients were female (60%) and white (78%). Forty patients had a recurrence of anterior uveitis. The incidence of relapse was 24% per person-year (95% confidence interval [CI], 17%-33%). At 1.5 years after remission, 61% (95% CI, 48%-71%) were still in remission. Younger adults had significantly higher relapse risk than middle-aged adults (hazard ratio [18- to 35-year-old persons vs. 35- to 55-year-old persons], 2.7; 95% CI, 1.3-6.0).
CONCLUSIONS: Our results suggest that many patients with remitted primary anterior uveitis presenting for tertiary uveitis care will relapse. Age in the young adult range was associated with higher risk of relapse. Given the high relapse risk, management of patients with primary anterior uveitis should include an explicit plan for detecting and managing relapses. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21680024      PMCID: PMC3179829          DOI: 10.1016/j.ophtha.2011.02.044

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Epidemiology of uveitis. Incidence and prevalence in a small urban community.

Authors:  R W DARRELL; H P WAGENER; L T KURLAND
Journal:  Arch Ophthalmol       Date:  1962-10

Review 2.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

Review 3.  The possible impact of uveitis in blindness: a literature survey.

Authors:  M S Suttorp-Schulten; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

Review 4.  Clinical features and associated systemic diseases of HLA-B27 uveitis.

Authors:  M L Tay-Kearney; B L Schwam; C Lowder; J P Dunn; D M Meisler; S Vitale; D A Jabs
Journal:  Am J Ophthalmol       Date:  1996-01       Impact factor: 5.258

5.  Clinical features of acute anterior uveitis.

Authors:  A Rothova; W G van Veenedaal; A Linssen; E Glasius; A Kijlstra; P T de Jong
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

6.  Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis.

Authors:  A Linssen; C Meenken
Journal:  Am J Ophthalmol       Date:  1995-09       Impact factor: 5.258

7.  Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.

Authors:  John H Kempen; Ebenezer Daniel; Sapna Gangaputra; Kurt Dreger; Douglas A Jabs; R Oktay Kaçmaz; Siddharth S Pujari; Fahd Anzaar; C Stephen Foster; Kathy J Helzlsouer; Grace A Levy-Clarke; Robert B Nussenblatt; Teresa Liesegang; James T Rosenbaum; Eric B Suhler
Journal:  Ophthalmic Epidemiol       Date:  2008 Jan-Feb       Impact factor: 1.648

8.  Outcomes in anterior uveitis associated with the HLA-B27 haplotype.

Authors:  W J Power; A Rodriguez; M Pedroza-Seres; C S Foster
Journal:  Ophthalmology       Date:  1998-09       Impact factor: 12.079

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.

Authors:  John H Kempen; Ebenezer Daniel; James P Dunn; C Stephen Foster; Sapna Gangaputra; Asaf Hanish; Kathy J Helzlsouer; Douglas A Jabs; R Oktay Kaçmaz; Grace A Levy-Clarke; Teresa L Liesegang; Craig W Newcomb; Robert B Nussenblatt; Siddharth S Pujari; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne
Journal:  BMJ       Date:  2009-07-03
View more
  6 in total

1.  Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema.

Authors:  Marc H Levin; Maxwell Pistilli; Ebenezer Daniel; Sapna S Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; John H Kempen
Journal:  Ophthalmology       Date:  2013-12-12       Impact factor: 12.079

2.  Factors Predictive of Remission of Chronic Anterior Uveitis.

Authors:  Lucia Sobrin; Maxwell Pistilli; Kurt Dreger; Srishti Kothari; Naira Khachatryan; Pichaporn Artornsombudh; Siddharth S Pujari; C Stephen Foster; Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum; Grace A Levy-Clarke; H Nida Sen; Eric B Suhler; Jennifer E Thorne; Nirali P Bhatt; John H Kempen
Journal:  Ophthalmology       Date:  2019-11-28       Impact factor: 12.079

3.  Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study.

Authors:  Maria D Pinazo-Durán; Jose J García-Medina; Silvia M Sanz-González; Jose E O'Connor; Ricardo P Casaroli-Marano; Mar Valero-Velló; Maribel López-Gálvez; Cristina Peris-Martínez; Vicente Zanón-Moreno; Manuel Diaz-Llopis
Journal:  Diagnostics (Basel)       Date:  2021-04-19

4.  A transcriptome atlas of the mouse iris at single-cell resolution defines cell types and the genomic response to pupil dilation.

Authors:  Jie Wang; Amir Rattner; Jeremy Nathans
Journal:  Elife       Date:  2021-11-16       Impact factor: 8.140

5.  A Novel Clinical Five-Risk Factor Panel for Individualized Recurrence Risk Assessment of Patients With Acute Anterior Uveitis.

Authors:  Xiwen Ji; Zicheng Zhang; Dan Lin; Mali Dai; Xia Zhao; Xingneng Guo; Jie Du; Meng Zhou; Yuqin Wang
Journal:  Transl Vis Sci Technol       Date:  2021-11-01       Impact factor: 3.283

6.  The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.

Authors:  Irene van der Horst-Bruinsma; Rianne van Bentum; Frank D Verbraak; Thomas Rath; James T Rosenbaum; Maria Misterska-Skora; Bengt Hoepken; Oscar Irvin-Sellers; Brenda VanLunen; Lars Bauer; Martin Rudwaleit
Journal:  RMD Open       Date:  2020-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.